glp-1 addiction Weight Loss Drugs May Also Curb Substance Use Disorders The Role of GLP-1 in

Both drugs belong to a family of modern therapies that have changed how clinicians treat diabetes and obesity

This analytical review critically examines the evidence surrounding GLP-1 agonists efficacy, safety, and real-world implications for obesity treatment in individuals without diabetes

Compounded GLP-1 + GIP Injections come from state-regulated 503A pharmacies to support weight loss

National Post reports generic semaglutide products could reach Canadian pharmacy shelves by summer 2026 as Health Canada reviews nine applications.

Deal Snapshot: Novo is partnering with Ascendis on less frequently dosed drugs for metabolic diseases, committing up to $285m for a lead program, a once-monthly GLP-1 receptor agonist.